Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5
Tel Aviv, 26 June 2012. Aspireo Pharmaceuticals Limited, a biopharmaceutical company focused on the development of a novel somatostatin analog, announced today that the research group of Prof. Schulz...
View ArticleEvotec and Aspireo enter into strategic advisory agreement
Teaming up to partner Aspireo’s Somatoprim (DG3173) Hamburg, Germany & Tel Aviv, Israel – 28 September 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and Aspireo Pharmaceuticals Limited...
View ArticleAspireo starts Somatoprim Phase IIa Study in Acromegaly Patients
First Patient Dosed in First Proof-Of-Concept Study in Untreated Acromegaly Patients Tel Aviv, Israel – 6th November 2012: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...
View ArticleAspireo Receives Positive Opinion from EMA for Orphan Disease Designation for...
Somatoprim Recommended For Designation as Orphan Medicinal Product for Acromegaly Tel Aviv, Israel – 26th November 2012: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...
View ArticleAspireo Reports Phase I b Interim Data for Somatoprim
Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim Tel Aviv, Israel – 7th January 2013: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical...
View ArticleAspireo Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly
Somatoprim reduces human growth hormone secretion safely and effectively in acromegaly patients Tel Aviv, Israel, 3rd April 2013: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli...
View ArticleAspireo Reports Start of Further Phase I Study in Healthy Volunteers
First subjects treated with Somatoprim or comparator in cross-over design Tel Aviv, Israel, 18th June 2013: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on...
View ArticleFDA Grants Orphan Drug Designation for Aspireo’s Somatoprim
Tel Aviv, Israel – 25 September 2013: Aspireo Pharmaceuticals Limited, (“Aspireo”) an Israeli biopharmaceutical company, focused on the development of Somatoprim, a novel somatostatin analog (SSA),...
View ArticleAspireo Reports Data in Further Phase Ib Study
Somatoprim Demonstrates Superior Side Effect Profile Over Octreotide Tel Aviv, Israel, 22 April 2014: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on the...
View ArticleAspireo’s Somatoprim (DG3173) Program Acquired by Cortendo for USD $30 Million
Sole Aspireo Investor, TVM Capital, to Participate in Cortendo Financing Tel Aviv, Israel, 18 May 2015: Aspireo Pharmaceuticals Limited (“Aspireo”), an Israeli biopharmaceutical company, focused on the...
View Article
More Pages to Explore .....